BioPharma APAC - Leading Source of Biopharmaceutical Intelligence in Asia Pacific

Duke Street Bio Secures FDA Fast Track Designation for DSB2455 in TNBC-Related Brain Metastases

Duke Street Bio, a clinical-stage biotechnology company focused on precision oncology, announced that the U.S. Food and Drug Administration (FDA) has...

June 25, 2025 | News

EVA Pharma and CHICO Pharmaceutical Join Forces to Localize Oncology API Production for Middle East and Africa

On the sidelines of CPHI China 2025, EVA Pharma, one of the leading pharmaceutical companies driving healthcare innovation and access across the Middle Eas...

June 25, 2025 | News

Daiichi Sankyo and AstraZeneca’s DATROWAY Receives U.S. FDA Accelerated Approval for EGFR-Mutated Lung Cancer

Based on TROPION-Lung05 phase 2 trial results and supported by data from the TROPION-Lung01 phase 3 trial Second U.S. approval for Daiichi Sankyo and ...

June 24, 2025 | News

Harbour BioMed and Otsuka Ink $670M+ Global Deal to Advance Bispecific T-Cell Engager for Autoimmune Diseases

Harbour BioMed, a global biopharmaceutical company committed to the discovery and development of novel antibody therapeutics in immunology and oncology,&nb...

June 23, 2025 | News

XtalPi and DoveTree Sign $100M+ LOI to Accelerate AI-Driven Drug Discovery Across Oncology and Neurology

XtalPi, a global leader in AI- and robotics-powered drug and materials discovery, announced it has signed a Letter of Intent (LOI) with DoveTre...

June 23, 2025 | News

Dizal Completes Enrollment for Global Phase III Trial of Sunvozertinib in EGFR exon20ins NSCLC Patients

Dizal announced the completion of patient enrollment for its WU-KONG28 clinical trial: a multinational, randomized phase III study evaluating the effi...

June 20, 2025 | News

Pierre Fabre Acquires Global Rights to Next-Generation EGFR Inhibitors for Lung Cancer

Pierre Fabre Laboratories are pleased to announce the acquisition from Antares Therapeutics, Inc. ("Antares"), a spin-out of Scorpion Therapeutics, Inc., o...

June 17, 2025 | News

Teva and Fosun Pharma Enter Strategic Partnership to Advance Anti-PD1-IL2 ATTENUKINE™ Therapy TEV-56278 for Oncology

Teva-engineered TEV-56278 is an anti-PD1-IL2 ATTENUKINE™ therapy in Phase 1 for the treatment of various forms of cancer, including melanoma Fosun...

June 17, 2025 | News

Gene Solutions and USKBio Partner to Launch AI-Powered NGS Oncology Lab in Southern China

- Gene Solutions, a leading multinational biotechnology company and Shenzhen USK Bioscience Co., Ltd. (USKBio), a prominent innovator i...

June 16, 2025 | News

Sanyou Biopharmaceuticals and Medicovestor Forge Strategic Partnership to Advance First-in-Class Chemoimmunotherapy ADCs

Sanyou Biopharmaceuticals, a leading Shanghai-based high-tech biopharmaceutical company specializing in biologics R&D announced the signing ...

June 11, 2025 | News

ASCO 2025 Showcases New Oncology Paradigms, From Breast Cancer Breakthroughs to AI-Led Precision Medicine

The 2025 American Society of Clinical Oncology (ASCO) Annual Meeting wasn’t just another scientific gathering and it was a seismic event that redrew ...

June 06, 2025 | Report

MGI Expands Partnership with Fiocruz’s UNADIG to Advance Genetic Sequencing in Brazil

MGI Tech Co., Ltd. ("MGI"), a company committed to building core tools and technologies that drive innovation in life science, has just expanded its partne...

June 06, 2025 | News

QureBio Secures Nearly CNY 100 Million in Series C1 Funding Led by Efung Capital

Qure Biotechnology (Shanghai) Co., Ltd. (QureBio) announced that it has completed a Series C1 financing round. The financing raised nearly CNY 100 mil...

June 06, 2025 | News

Innovent and HUTCHMED’s Sintilimab-Fruquintinib Combo Accepted for NMPA Review in Advanced Renal Cell Carcinoma

Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality me...

June 05, 2025 | News

Stay Connected